Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Working Capital Changes: 2009-2024

Historic Other Working Capital Changes for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$7.7 million.

  • Lineage Cell Therapeutics' Other Working Capital Changes rose 47.42% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year decrease of 18.53%. This contributed to the annual value of -$7.7 million for FY2024, which is 0.46% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Other Working Capital Changes of -$7.7 million as of FY2024, which was down 0.46% from -$7.6 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Other Working Capital Changes high stood at $380,000 for FY2021, and its period low was -$13.4 million during FY2022.
  • For the 3-year period, Lineage Cell Therapeutics' Other Working Capital Changes averaged around -$9.6 million, with its median value being -$7.7 million (2024).
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Working Capital Changes surged by 124.13% in 2021 and then crashed by 3,614.21% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Other Working Capital Changes stood at -$1.6 million in 2020, then spiked by 124.13% to $380,000 in 2021, then tumbled by 3,614.21% to -$13.4 million in 2022, then spiked by 42.75% to -$7.6 million in 2023, then fell by 0.46% to -$7.7 million in 2024.